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p38 and STAT3 activation that is NFjB-independent. We demon-
strate further that Src activation contributes to the expression
of the transcriptional repressor, Id2 (Inhibitor of differentiation
2), expressed in pancreatic (and some other) tumor cells but not
in normal adult cells. Expression of Id-2 is regulated transcrip-
tionally by Hif-1a, and, in turn, Id-2 regulates Hif-1a stability,
thereby contributing to increased expression of VEGF in tumor
cells. These results suggest that Src activation deregulates multi-
ple pro-angiogenic programs that may provide markers as well as
targets for novel therapies.
doi:10.1016/j.ejcsup.2006.04.003
S3. AP-1-DEPENDENT GENE EXPRESSION DURING SKIN
TUMOURIGENESIS
Peter Angel. Deutsches Krebsforschungszentrum, Division Signal
Transduction and Growth Control, Heidelberg, Germany.
The transcription factor AP-1, which is composed of members of
the Fos, Jun and ATF protein families participates in physiologi-
cal and pathophysiological processes due to its central role as a
cellular switch of genetic programs in response to extracellular
signals. The distinct expression pattern of AP-1 subunits in the
skin, the loss of chemically induced carcinogenesis in AP-1 com-
promised mice, and the large number of putative AP-1 target
genes in epidermal cells, indicate that AP-1 members play a piv-
otal role in epidermal organisation, skin homeostasis and tumo-
urigenesis. To define AP-1-dependent genetic programs
associated with distinct stages of tumourigenesis in vivo we
have combined the well-established chemically induced mouse
model of epithelial skin tumours and comprehensive expression
profiling. A series of novel tumour-associated genes could be
identified including previously unrecognized molecules involved
in protein trafficking and novel serine and aspartic proteases,
which are expressed depending on the differentiation and pro-
gression state of the tumours. Moreover, four members of the
S100 family of Ca2+ binding proteins, S100A3, A6 and A8, A9 were
identified, which are differentially expressed in murine and
human epithelial tumours of the skin and other organs. These
molecules are part of a novel signalling pathway controlling
AP-1 and NFjB-dependent genetic programs, which are likely
to play an important role in tumour formation, progression
and metastasis.
doi:10.1016/j.ejcsup.2006.04.004
S4. ENZASTAURIN – FROM BENCH TO BEDSIDE, AND BACK
Manfred Lehnert. Eli Lilly and Company, Oncology Platform Team,
Indianapolis, IN, USA.
Enzastaurin is an oral serine-threonine kinase inhibitor of the
PI3K signaling pathway and PKCb. In preclinical in vitro and
in vivo tumor models, enzastaurin promotes apoptosis, inhibits
tumor cell proliferation and blocks tumor-induced angiogenesis.
Phase II studies showed encouraging efficacy in heavily pre-
treated patients with glioblastoma multiforme and diffuse large
B cell lymphomas, respectively. Prospective randomized phase
III trials are about to commence in these two tumor types. Phase
II trials are in progress or development in a variety of cancers,
including breast, ovarian, colon, prostate, non-small cell lung
cancer, chronic lymphocytic leukemia and follicular lymphomas.
The available safety data show good tolerance of enzastaurin
when used as a single agent. Phase I studies in combination with
various cancer agents, cytotoxic as well as biologically targeted,
are in progress. Most enzastaurin trials include tumor tissue col-
lection for correlative analysis of candidate biomarkers and clin-
ical outcome. We hope this will allow selection of those cancer
patients in the future who gain most benefit from enzastaurin
treatment.
doi:10.1016/j.ejcsup.2006.04.005
S5. SURVIVING AND TRANSFORMING GROWTH FACTOR BETA
(TGF-b) AS DRUG TARGETS IN CANCER
Michael Lahn. Oncology Therapeutic Area, Lilly Research Laboratories,
Indianapolis, IN, USA.
The molecular heterogeneity of malignant cells and their interac-
tion with the surrounding microenvironment is one of the most
challenging aspects of drug development in oncology. Developing
successful drug intervention strategies requires the identification
of molecular targets that show high impact on either tumor cell
growth or the supporting microenvironment. In recent years, sev-
eral such targets have been proposed, including Survivin and
TGF-b. Survivin is uniquely upregulated in most cancer cells,
while in non-malignant cells it is generally not expressed. Thus,
an inhibition of Survivin could lead to a selective treatment of
malignant cells without affecting normal tissue cells. Because of
its structure, selective small molecule inhibitors are difficult to
identify.
In collaboration with Isis Pharmaceuticals (Carlsbad, CA, USA)
Eli Lilly and Company (Indianapolis, IN, USA) (Lilly) developed a
second generation antisense oligonucleotide (ASO) that is specific
for the inhibition of Survivin in cells. This ASO against Survivin
has been evaluated in various non-clinical in vitro and in vivo
models confirming its specificity. Based on this information, a
phase I clinical trial was started to evaluate its safety and phar-
macokinetic profile in cancer patients. In contrast to a target in
cancer cells, inhibiting TGF-b signaling is designed to modulate
the microenvironment of cancer cells. Lilly developed various
small molecule inhibitors for the TGF-b receptor type I (TGF-
bRI) kinase. From this series of molecules, one inhibitor has been
selected for clinical investigation. The compound LY2157299 has
demonstrated anti-tumor activity in various non-clinical
in vitro and in vivo models, supporting its evaluation in a phase
I clinical trial of patients with cancer. In summary, Lilly has a
comprehensive program to develop inhibitors of tumor cells
and their supporting microenvironment, such as Survivin and
TGF-b.
doi:10.1016/j.ejcsup.2006.04.006
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